Palisade Bio, Inc. is a biopharmaceutical company founded with the mission to identify, develop, and commercialize novel therapeutics targeting diseases resulting from a loss of gastrointestinal barrier integrity. The company's vision is to transform the treatment of gastrointestinal (GI) diseases by protecting intestinal barrier health. Palisade Bio focuses on developing therapies for acute and chronic GI complications, including conditions like Inflammatory Bowel Disease (IBD), Crohn’s Disease, and Ulcerative Colitis. Their innovative approach aims to provide precision delivery for patient-tailored therapies that protect intestinal integrity.

Notable figures affiliated with Palisade Bio include experienced professionals in the biopharmaceutical industry and key investors who support the company's groundbreaking work. The company has achieved significant milestones in advancing its pipeline of therapeutic candidates, demonstrating promising preclinical and clinical results. Palisade Bio's impact is marked by its commitment to improving the lives of patients worldwide suffering from debilitating GI conditions, positioning itself as a leader in the field of gastrointestinal health.